vimarsana.com

Latest Breaking News On - Treating advanced - Page 1 : vimarsana.com

Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

Dato-DXd for Treating Advanced NSCLC

Benjamin Levy, MD, reviews clinical data on Dato-DXd in patients with advanced NSCLC and their practical implications.

T-DXd in HER2 Mutated Advanced NSCLC

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

Molecular Testing in Advanced NSCLC

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.